Market Research Logo

Genmab A/S - Product Pipeline Review - 2016

Genmab A/S - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Genmab A/S - Product Pipeline Review - 2016’, provides an overview of the Genmab A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genmab A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Genmab A/S
  • The report provides overview of Genmab A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Genmab A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Genmab A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Genmab A/S’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genmab A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genmab A/S’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Genmab A/S Snapshot
Genmab A/S Overview
Key Information
Key Facts
Genmab A/S - Research and Development Overview
Key Therapeutic Areas
Genmab A/S - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Genmab A/S - Pipeline Products Glance
Genmab A/S - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Genmab A/S - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Genmab A/S - Drug Profiles
teprotumumab
Product Description
Mechanism of Action
R&D Progress
tisotumab vedotin
Product Description
Mechanism of Action
R&D Progress
HuMax-AXL-ADC
Product Description
Mechanism of Action
R&D Progress
IDD-004
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 1 for Central Nervous System Disorders
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 2 for Central Nervous System Disorders
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 3 for Central Nervous System Disorders
Product Description
Mechanism of Action
R&D Progress
Mononclonal Antibody 1 for Oncology
Product Description
Mechanism of Action
R&D Progress
Mononclonal Antibody 2 for Oncology
Product Description
Mechanism of Action
R&D Progress
Mononclonal Antibody Conjugate for Oncology
Product Description
Mechanism of Action
R&D Progress
Genmab A/S - Pipeline Analysis
Genmab A/S - Pipeline Products by Target
Genmab A/S - Pipeline Products by Route of Administration
Genmab A/S - Pipeline Products by Molecule Type
Genmab A/S - Pipeline Products by Mechanism of Action
Genmab A/S - Recent Pipeline Updates
Genmab A/S - Dormant Projects
Genmab A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
HuMax-CD74-ADC
teprotumumab
Genmab A/S - Company Statement
Genmab A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Genmab A/S, Key Information
Genmab A/S, Key Facts
Genmab A/S - Pipeline by Indication, 2016
Genmab A/S - Pipeline by Stage of Development, 2016
Genmab A/S - Monotherapy Products in Pipeline, 2016
Genmab A/S - Partnered Products in Pipeline, 2016
Genmab A/S - Partnered Products/ Combination Treatment Modalities, 2016
Genmab A/S - Out-Licensed Products in Pipeline, 2016
Genmab A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016
Genmab A/S - Phase II, 2016
Genmab A/S - Phase I, 2016
Genmab A/S - Preclinical, 2016
Genmab A/S - Pipeline by Target, 2016
Genmab A/S - Pipeline by Route of Administration, 2016
Genmab A/S - Pipeline by Molecule Type, 2016
Genmab A/S - Pipeline Products by Mechanism of Action, 2016
Genmab A/S - Recent Pipeline Updates, 2016
Genmab A/S - Dormant Developmental Projects,2016
Genmab A/S - Discontinued Pipeline Products, 2016
Genmab A/S, Subsidiaries
List of Figures
Genmab A/S - Pipeline by Top
Genmab A/S - Pipeline by Stage of Development,
Genmab A/S - Monotherapy Products in Pipeline,
Genmab A/S - Partnered Products in Pipeline,
Genmab A/S - Out-Licensed Products in Pipeline,
Genmab A/S - Pipeline by Target,
Genmab A/S - Pipeline by Route of Administration,
Genmab A/S - Pipeline by Molecule Type,
Genmab A/S - Pipeline Products by Mechanism of Action,

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report